Office of the Vice Provost for ResearchEncouraging, cultivating, and coordinating high-impact academic research across Harvard’s schools and affiliated institutions
Covid-19 Related Information
Harvard University is closely monitoring the ongoing Coronavirus Disease 2019 (COVID-19) outbreak. As the situation continues to change rapidly, our top priority remains the health, safety, and well-being of our community, on and off campus. For all up-to-date information, including university-wide and school specific recommendations, workforce planning, travel guidance, and meeting and event guidance, please see the main Harvard University Coronavirus (COVID-19) webpage.
Featured Strategic Initiative: Landmark Bio, PBLLC
Spearheaded by the OVPR, Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today’s cutting-edge research into tomorrow’s breakthrough therapies. With construction starting on the new 40,000 square-foot biomanufacturing facility at The Arsenal on the Charles in Watertown, MA, Landmark Bio plans to begin opening at the start of 2022. The initial focus of the facility will include cell and gene therapy, gene editing, and mRNA products, which offer the potential to treat or even cure diseases such as cancer, diabetes, Parkinson’s, and Alzheimer’s, among others.